JPS59500965A

JPS59500965A - 循環機能改善のための、化合物、組成物および治療方法

循環機能改善のための、化合物、組成物および治療方法

Info

Publication number: JPS59500965A
Authority: JP; Japan
Prior art keywords: berberine; compounds; heart; group; pressure
Prior art date: 1982-05-14
Legal status : Granted

Application number

JP58502179A

Other languages

English (en)

Japanese (ja)

Other versions

JPH0463857B2 (enExample

Inventor

マロコ，ペ−タ−・ア−ル

Current Assignee

Individual

Original Assignee

Individual

Priority date

1982-05-14

Filing date

1983-05-13

Publication date

1984-05-31

1983-05-13 Application filed by Individual filed Critical Individual

1983-05-13 Priority claimed from PCT/US1983/000729 external-priority patent/WO1983003970A1/en

1984-05-31 Publication of JPS59500965A publication Critical patent/JPS59500965A/ja

1992-10-13 Publication of JPH0463857B2 publication Critical patent/JPH0463857B2/ja

Status Granted legal-status Critical Current

Links

150000001875 compounds Chemical class 0.000 title claims description 216
239000000203 mixture Substances 0.000 title claims description 53
238000002560 therapeutic procedure Methods 0.000 title description 4
QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 claims description 213
229940093265 berberine Drugs 0.000 claims description 213
YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 claims description 209
230000000694 effects Effects 0.000 claims description 155
210000002216 heart Anatomy 0.000 claims description 138
230000007423 decrease Effects 0.000 claims description 91
206010003119 arrhythmia Diseases 0.000 claims description 75
230000000747 cardiac effect Effects 0.000 claims description 75
230000006793 arrhythmia Effects 0.000 claims description 73
230000002861 ventricular Effects 0.000 claims description 68
206010019280 Heart failures Diseases 0.000 claims description 64
230000003247 decreasing effect Effects 0.000 claims description 62
230000004872 arterial blood pressure Effects 0.000 claims description 44
241001465754 Metazoa Species 0.000 claims description 42
230000017531 blood circulation Effects 0.000 claims description 36
210000004369 blood Anatomy 0.000 claims description 35
239000008280 blood Substances 0.000 claims description 35
238000000034 method Methods 0.000 claims description 33
230000009471 action Effects 0.000 claims description 30
229910052698 phosphorus Inorganic materials 0.000 claims description 30
-1 protoberberine alkaloid compound Chemical class 0.000 claims description 30
230000001225 therapeutic effect Effects 0.000 claims description 28
239000011574 phosphorus Substances 0.000 claims description 26
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical class [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 25
230000003288 anthiarrhythmic effect Effects 0.000 claims description 25
210000003205 muscle Anatomy 0.000 claims description 25
230000036581 peripheral resistance Effects 0.000 claims description 25
UICBHOXXGLYZJH-UHFFFAOYSA-N 5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium Chemical group C1=CC=C2CC[N+]3=CC4=CC=CC=C4C=C3C2=C1 UICBHOXXGLYZJH-UHFFFAOYSA-N 0.000 claims description 24
241000124008 Mammalia Species 0.000 claims description 24
229930182470 glycoside Natural products 0.000 claims description 24
150000002338 glycosides Chemical class 0.000 claims description 24
229930013930 alkaloid Natural products 0.000 claims description 23
150000003839 salts Chemical class 0.000 claims description 23
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 22
230000000297 inotrophic effect Effects 0.000 claims description 21
AEQDJSLRWYMAQI-UHFFFAOYSA-N Tetrahydropalmatine Natural products C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 claims description 17
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 16
230000009885 systemic effect Effects 0.000 claims description 16
231100001274 therapeutic index Toxicity 0.000 claims description 14
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 12
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
229940097217 cardiac glycoside Drugs 0.000 claims description 11
239000002368 cardiac glycoside Substances 0.000 claims description 11
229930002534 steroid glycoside Natural products 0.000 claims description 11
125000004432 carbon atom Chemical group C* 0.000 claims description 10
229930001510 protoberberine alkaloid Natural products 0.000 claims description 10
150000008143 steroidal glycosides Chemical class 0.000 claims description 10
230000036316 preload Effects 0.000 claims description 9
230000005796 circulatory shock Effects 0.000 claims description 8
230000024883 vasodilation Effects 0.000 claims description 8
238000000605 extraction Methods 0.000 claims description 6
229910052757 nitrogen Inorganic materials 0.000 claims description 6
229920006395 saturated elastomer Polymers 0.000 claims description 5
238000010521 absorption reaction Methods 0.000 claims description 4
125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
238000003306 harvesting Methods 0.000 claims description 2
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 2
229910052751 metal Inorganic materials 0.000 claims description 2
239000002184 metal Substances 0.000 claims description 2
150000003017 phosphorus Chemical class 0.000 claims description 2
230000002265 prevention Effects 0.000 claims description 2
230000001105 regulatory effect Effects 0.000 claims description 2
BWUQAWCUJMATJS-HNNXBMFYSA-N (-)-Coreximine Natural products C1C2=CC(OC)=C(O)C=C2C[C@@H]2N1CCC1=C2C=C(O)C(OC)=C1 BWUQAWCUJMATJS-HNNXBMFYSA-N 0.000 claims 1
239000002260 anti-inflammatory agent Substances 0.000 claims 1
229940124599 anti-inflammatory drug Drugs 0.000 claims 1
230000002708 enhancing effect Effects 0.000 claims 1
229910052611 pyroxene Inorganic materials 0.000 claims 1
238000000718 qrs complex Methods 0.000 claims 1
AEQDJSLRWYMAQI-KRWDZBQOSA-N tetrahydropalmatine Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3C[C@H]2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-KRWDZBQOSA-N 0.000 claims 1
241000282472 Canis lupus familiaris Species 0.000 description 107
238000011282 treatment Methods 0.000 description 99
240000001879 Digitalis lutea Species 0.000 description 87
239000003814 drug Substances 0.000 description 80
229940079593 drug Drugs 0.000 description 68
230000035939 shock Effects 0.000 description 55
230000008859 change Effects 0.000 description 47
238000002347 injection Methods 0.000 description 47
239000007924 injection Substances 0.000 description 47
230000035487 diastolic blood pressure Effects 0.000 description 30
238000002474 experimental method Methods 0.000 description 24
238000001802 infusion Methods 0.000 description 21
244000166550 Strophanthus gratus Species 0.000 description 19
230000009286 beneficial effect Effects 0.000 description 19
230000036772 blood pressure Effects 0.000 description 19
230000002107 myocardial effect Effects 0.000 description 19
AEQDJSLRWYMAQI-QGZVFWFLSA-N (13ar)-2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5h-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3C[C@@H]2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-QGZVFWFLSA-N 0.000 description 18
230000006870 function Effects 0.000 description 18
LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 18
230000035485 pulse pressure Effects 0.000 description 18
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
LPMXVESGRSUGHW-UHFFFAOYSA-N Acolongiflorosid K Natural products OC1C(O)C(O)C(C)OC1OC1CC2(O)CCC3C4(O)CCC(C=5COC(=O)C=5)C4(C)CC(O)C3C2(CO)C(O)C1 LPMXVESGRSUGHW-UHFFFAOYSA-N 0.000 description 17
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 17
LPMXVESGRSUGHW-GHYGWZAOSA-N Ouabain Natural products O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1)[C@H]1C[C@@H](O)[C@@]2(CO)[C@@](O)(C1)CC[C@H]1[C@]3(O)[C@@](C)([C@H](C4=CC(=O)OC4)CC3)C[C@@H](O)[C@H]21 LPMXVESGRSUGHW-GHYGWZAOSA-N 0.000 description 17
229960003343 ouabain Drugs 0.000 description 17
230000035488 systolic blood pressure Effects 0.000 description 17
238000012360 testing method Methods 0.000 description 16
241000700159 Rattus Species 0.000 description 15
230000001154 acute effect Effects 0.000 description 15
239000008121 dextrose Substances 0.000 description 15
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
230000009090 positive inotropic effect Effects 0.000 description 15
230000009467 reduction Effects 0.000 description 15
230000002829 reductive effect Effects 0.000 description 15
239000003795 chemical substances by application Substances 0.000 description 14
210000004165 myocardium Anatomy 0.000 description 14
239000003416 antiarrhythmic agent Substances 0.000 description 13
210000000056 organ Anatomy 0.000 description 13
230000002792 vascular Effects 0.000 description 13
206010007559 Cardiac failure congestive Diseases 0.000 description 12
230000034994 death Effects 0.000 description 12
231100000517 death Toxicity 0.000 description 12
201000010099 disease Diseases 0.000 description 12
230000000004 hemodynamic effect Effects 0.000 description 12
230000036513 peripheral conductance Effects 0.000 description 12
230000010102 embolization Effects 0.000 description 11
208000019622 heart disease Diseases 0.000 description 11
238000001990 intravenous administration Methods 0.000 description 11
238000010253 intravenous injection Methods 0.000 description 11
238000005259 measurement Methods 0.000 description 11
239000000243 solution Substances 0.000 description 11
239000000126 substance Substances 0.000 description 11
VKJGBAJNNALVAV-UHFFFAOYSA-M Berberine chloride (TN) Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 VKJGBAJNNALVAV-UHFFFAOYSA-M 0.000 description 10
241000282414 Homo sapiens Species 0.000 description 10
208000001871 Tachycardia Diseases 0.000 description 10
125000000217 alkyl group Chemical group 0.000 description 10
210000000709 aorta Anatomy 0.000 description 10
230000008901 benefit Effects 0.000 description 10
230000033764 rhythmic process Effects 0.000 description 10
208000024891 symptom Diseases 0.000 description 10
230000006794 tachycardia Effects 0.000 description 10
206010007556 Cardiac failure acute Diseases 0.000 description 9
150000001299 aldehydes Chemical class 0.000 description 9
150000003797 alkaloid derivatives Chemical class 0.000 description 9
230000015572 biosynthetic process Effects 0.000 description 9
229910052799 carbon Inorganic materials 0.000 description 9
230000001684 chronic effect Effects 0.000 description 9
230000033001 locomotion Effects 0.000 description 9
230000036284 oxygen consumption Effects 0.000 description 9
230000004044 response Effects 0.000 description 9
241000282412 Homo Species 0.000 description 8
239000004480 active ingredient Substances 0.000 description 8
230000008602 contraction Effects 0.000 description 8
230000006872 improvement Effects 0.000 description 8
239000004041 inotropic agent Substances 0.000 description 8
230000002093 peripheral effect Effects 0.000 description 8
230000000144 pharmacologic effect Effects 0.000 description 8
230000000638 stimulation Effects 0.000 description 8
241000282326 Felis catus Species 0.000 description 7
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
239000002253 acid Substances 0.000 description 7
238000004458 analytical method Methods 0.000 description 7
239000002585 base Substances 0.000 description 7
210000004204 blood vessel Anatomy 0.000 description 7
238000010586 diagram Methods 0.000 description 7
LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 7
239000002158 endotoxin Substances 0.000 description 7
230000001976 improved effect Effects 0.000 description 7
210000005240 left ventricle Anatomy 0.000 description 7
230000028161 membrane depolarization Effects 0.000 description 7
241000894007 species Species 0.000 description 7
208000003663 ventricular fibrillation Diseases 0.000 description 7
206010063081 Acute left ventricular failure Diseases 0.000 description 6
208000024172 Cardiovascular disease Diseases 0.000 description 6
206010011086 Coronary artery occlusion Diseases 0.000 description 6
WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 6
LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 6
206010040070 Septic Shock Diseases 0.000 description 6
UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 6
RNLQIBCLLYYYFJ-UHFFFAOYSA-N amrinone Chemical compound N1C(=O)C(N)=CC(C=2C=CN=CC=2)=C1 RNLQIBCLLYYYFJ-UHFFFAOYSA-N 0.000 description 6
GLYPKDKODVRYGP-UHFFFAOYSA-N burberrubine Natural products C12=CC=3OCOC=3C=C2CCN2C1=CC1=CC=C(OC)C(=O)C1=C2 GLYPKDKODVRYGP-UHFFFAOYSA-N 0.000 description 6
150000003943 catecholamines Chemical class 0.000 description 6
210000004351 coronary vessel Anatomy 0.000 description 6
230000003001 depressive effect Effects 0.000 description 6
229960000648 digitoxin Drugs 0.000 description 6
WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 6
229960005156 digoxin Drugs 0.000 description 6
LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 6
235000013399 edible fruits Nutrition 0.000 description 6
210000003734 kidney Anatomy 0.000 description 6
210000004185 liver Anatomy 0.000 description 6
239000002207 metabolite Substances 0.000 description 6
208000010125 myocardial infarction Diseases 0.000 description 6
229910052760 oxygen Inorganic materials 0.000 description 6
210000005259 peripheral blood Anatomy 0.000 description 6
239000011886 peripheral blood Substances 0.000 description 6
LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 6
230000001603 reducing effect Effects 0.000 description 6
238000011160 research Methods 0.000 description 6
231100000331 toxic Toxicity 0.000 description 6
230000002588 toxic effect Effects 0.000 description 6
XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 description 5
XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 description 5
241001083847 Berberis Species 0.000 description 5
241000196324 Embryophyta Species 0.000 description 5
102000051325 Glucagon Human genes 0.000 description 5
108060003199 Glucagon Proteins 0.000 description 5
241000699670 Mus sp. Species 0.000 description 5
239000004698 Polyethylene Substances 0.000 description 5
206010060953 Ventricular failure Diseases 0.000 description 5
229940039750 aconitine Drugs 0.000 description 5
STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 description 5
230000002411 adverse Effects 0.000 description 5
239000003513 alkali Substances 0.000 description 5
125000003545 alkoxy group Chemical group 0.000 description 5
229960002105 amrinone Drugs 0.000 description 5
239000007864 aqueous solution Substances 0.000 description 5
125000003118 aryl group Chemical group 0.000 description 5
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
150000001721 carbon Chemical group 0.000 description 5
230000003205 diastolic effect Effects 0.000 description 5
231100000673 dose–response relationship Toxicity 0.000 description 5
230000002526 effect on cardiovascular system Effects 0.000 description 5
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 5
229960004666 glucagon Drugs 0.000 description 5
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 5
230000004217 heart function Effects 0.000 description 5
230000000302 ischemic effect Effects 0.000 description 5
239000004005 microsphere Substances 0.000 description 5
239000001301 oxygen Substances 0.000 description 5
229920000573 polyethylene Polymers 0.000 description 5
229910052700 potassium Inorganic materials 0.000 description 5
210000002784 stomach Anatomy 0.000 description 5
125000001424 substituent group Chemical group 0.000 description 5
230000002195 synergetic effect Effects 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
230000004873 systolic arterial blood pressure Effects 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
230000009278 visceral effect Effects 0.000 description 5
206010002091 Anaesthesia Diseases 0.000 description 4
206010014824 Endotoxic shock Diseases 0.000 description 4
241000283086 Equidae Species 0.000 description 4
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
206010024119 Left ventricular failure Diseases 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
230000005856 abnormality Effects 0.000 description 4
239000000556 agonist Substances 0.000 description 4
QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 4
230000037005 anaesthesia Effects 0.000 description 4
230000003126 arrythmogenic effect Effects 0.000 description 4
125000004104 aryloxy group Chemical group 0.000 description 4
239000000496 cardiotonic agent Substances 0.000 description 4
239000003638 chemical reducing agent Substances 0.000 description 4
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 4
230000001276 controlling effect Effects 0.000 description 4
210000003743 erythrocyte Anatomy 0.000 description 4
210000001105 femoral artery Anatomy 0.000 description 4
230000009931 harmful effect Effects 0.000 description 4
230000002008 hemorrhagic effect Effects 0.000 description 4
AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 4
239000007788 liquid Substances 0.000 description 4
208000031225 myocardial ischemia Diseases 0.000 description 4
210000005036 nerve Anatomy 0.000 description 4
230000001151 other effect Effects 0.000 description 4
125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 4
238000012545 processing Methods 0.000 description 4
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
GPTFURBXHJWNHR-UHFFFAOYSA-N protopine Chemical compound C1=C2C(=O)CC3=CC=C4OCOC4=C3CN(C)CCC2=CC2=C1OCO2 GPTFURBXHJWNHR-UHFFFAOYSA-N 0.000 description 4
238000005086 pumping Methods 0.000 description 4
230000002285 radioactive effect Effects 0.000 description 4
230000011514 reflex Effects 0.000 description 4
206010040560 shock Diseases 0.000 description 4
FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 4
208000011580 syndromic disease Diseases 0.000 description 4
230000001988 toxicity Effects 0.000 description 4
231100000419 toxicity Toxicity 0.000 description 4
210000002700 urine Anatomy 0.000 description 4
206010047302 ventricular tachycardia Diseases 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
206010003658 Atrial Fibrillation Diseases 0.000 description 3
206010003671 Atrioventricular Block Diseases 0.000 description 3
241000894006 Bacteria Species 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
241000282465 Canis Species 0.000 description 3
206010012735 Diarrhoea Diseases 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
208000001953 Hypotension Diseases 0.000 description 3
206010021138 Hypovolaemic shock Diseases 0.000 description 3
241000219745 Lupinus Species 0.000 description 3
208000021642 Muscular disease Diseases 0.000 description 3
201000009623 Myopathy Diseases 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
241000555745 Sciuridae Species 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
206010047139 Vasoconstriction Diseases 0.000 description 3
206010047281 Ventricular arrhythmia Diseases 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
239000000654 additive Substances 0.000 description 3
230000000996 additive effect Effects 0.000 description 3
239000000808 adrenergic beta-agonist Substances 0.000 description 3
208000003455 anaphylaxis Diseases 0.000 description 3
150000001450 anions Chemical class 0.000 description 3
230000002921 anti-spasmodic effect Effects 0.000 description 3
150000003832 berberine derivatives Chemical class 0.000 description 3
150000003836 berberines Chemical group 0.000 description 3
230000000975 bioactive effect Effects 0.000 description 3
230000005540 biological transmission Effects 0.000 description 3
239000002371 cardiac agent Substances 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 3
230000004087 circulation Effects 0.000 description 3
239000004020 conductor Substances 0.000 description 3
230000006378 damage Effects 0.000 description 3
OBATZBGFDSVCJD-UHFFFAOYSA-N de-O-acetyl-lanatoside C Natural products CC1OC(OC2CC3C(C4C(C5(CCC(C5(C)C(O)C4)C=4COC(=O)C=4)O)CC3)(C)CC2)CC(O)C1OC(OC1C)CC(O)C1OC(OC1C)CC(O)C1OC1OC(CO)C(O)C(O)C1O OBATZBGFDSVCJD-UHFFFAOYSA-N 0.000 description 3
229960001324 deslanoside Drugs 0.000 description 3
OBATZBGFDSVCJD-LALPQLPRSA-N deslanoside Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@@H]1C[C@@H]2[C@]([C@@H]3[C@H]([C@]4(CC[C@@H]([C@@]4(C)[C@H](O)C3)C=3COC(=O)C=3)O)CC2)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O OBATZBGFDSVCJD-LALPQLPRSA-N 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
239000002934 diuretic Substances 0.000 description 3
229940088598 enzyme Drugs 0.000 description 3
230000029142 excretion Effects 0.000 description 3
238000011049 filling Methods 0.000 description 3
239000012530 fluid Substances 0.000 description 3
210000002837 heart atrium Anatomy 0.000 description 3
230000010247 heart contraction Effects 0.000 description 3
239000003701 inert diluent Substances 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
230000003601 intercostal effect Effects 0.000 description 3
229910052740 iodine Inorganic materials 0.000 description 3
229930013397 isoquinoline alkaloid Natural products 0.000 description 3
230000007774 longterm Effects 0.000 description 3
230000014759 maintenance of location Effects 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
239000003550 marker Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
230000002503 metabolic effect Effects 0.000 description 3
230000003647 oxidation Effects 0.000 description 3
238000007254 oxidation reaction Methods 0.000 description 3
230000007170 pathology Effects 0.000 description 3
230000008092 positive effect Effects 0.000 description 3
229960001404 quinidine Drugs 0.000 description 3
210000001013 sinoatrial node Anatomy 0.000 description 3
230000002269 spontaneous effect Effects 0.000 description 3
230000002459 sustained effect Effects 0.000 description 3
230000002889 sympathetic effect Effects 0.000 description 3
230000002936 tranquilizing effect Effects 0.000 description 3
229910052721 tungsten Inorganic materials 0.000 description 3
230000036325 urinary excretion Effects 0.000 description 3
229940124549 vasodilator Drugs 0.000 description 3
239000003071 vasodilator agent Substances 0.000 description 3
239000000052 vinegar Substances 0.000 description 3
235000021419 vinegar Nutrition 0.000 description 3
JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 2
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
229930182837 (R)-adrenaline Natural products 0.000 description 2
BHLYRWXGMIUIHG-HNNXBMFYSA-N (S)-reticuline Chemical compound C1=C(O)C(OC)=CC=C1C[C@H]1C2=CC(O)=C(OC)C=C2CCN1C BHLYRWXGMIUIHG-HNNXBMFYSA-N 0.000 description 2
BEIZGBSEZACCGQ-UHFFFAOYSA-N 2,9,10-trimethoxy-6,8,13,13a-tetrahydro-5h-isoquinolino[2,1-b]isoquinolin-1-ol Chemical compound C1=CC(OC)=C(OC)C2=C1CC1C3=C(O)C(OC)=CC=C3CCN1C2 BEIZGBSEZACCGQ-UHFFFAOYSA-N 0.000 description 2
FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
206010002198 Anaphylactic reaction Diseases 0.000 description 2
206010002383 Angina Pectoris Diseases 0.000 description 2
241000269350 Anura Species 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
241000218645 Cedrus Species 0.000 description 2
244000304921 Charybdis maritima Species 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
241000208011 Digitalis Species 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
208000032843 Hemorrhage Diseases 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
206010062717 Increased upper airway secretion Diseases 0.000 description 2
MXTLAHSTUOXGQF-UHFFFAOYSA-O Jatrorrhizine Chemical compound COC1=CC=C2C=C3C(C=C(C(=C4)O)OC)=C4CC[N+]3=CC2=C1OC MXTLAHSTUOXGQF-UHFFFAOYSA-O 0.000 description 2
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
102100026933 Myelin-associated neurite-outgrowth inhibitor Human genes 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
PTPHDVKWAYIFRX-UHFFFAOYSA-N Palmatine Natural products C1C2=C(OC)C(OC)=CC=C2C=C2N1CCC1=C2C=C(OC)C(OC)=C1 PTPHDVKWAYIFRX-UHFFFAOYSA-N 0.000 description 2
208000005374 Poisoning Diseases 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
GTRPODKMSBFDOI-UHFFFAOYSA-N Protopine Natural products CN1Cc2c3OCOc3ccc2C4C1Cc5cc6OCOc6cc5C4=O GTRPODKMSBFDOI-UHFFFAOYSA-N 0.000 description 2
ZAALQOFZFANFTF-UHFFFAOYSA-N Pseudoprotipine Natural products C1=C2C(=O)CC3=CC=4OCOC=4C=C3CN(C)CCC2=CC2=C1OCO2 ZAALQOFZFANFTF-UHFFFAOYSA-N 0.000 description 2
208000028017 Psychotic disease Diseases 0.000 description 2
206010040047 Sepsis Diseases 0.000 description 2
206010049771 Shock haemorrhagic Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
241000282887 Suidae Species 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
206010042600 Supraventricular arrhythmias Diseases 0.000 description 2
239000000150 Sympathomimetic Substances 0.000 description 2
206010057469 Vascular stenosis Diseases 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
230000001133 acceleration Effects 0.000 description 2
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
229960004373 acetylcholine Drugs 0.000 description 2
DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
230000001476 alcoholic effect Effects 0.000 description 2
238000002583 angiography Methods 0.000 description 2
230000003042 antagnostic effect Effects 0.000 description 2
230000008485 antagonism Effects 0.000 description 2
230000002663 anti-arrhythmogenic effect Effects 0.000 description 2
230000001142 anti-diarrhea Effects 0.000 description 2
230000002467 anti-pepsin effect Effects 0.000 description 2
210000002376 aorta thoracic Anatomy 0.000 description 2
BZKUYNBAFQJRDM-UHFFFAOYSA-N aporphine Chemical compound C12=CC=CC=C2CC2N(C)CCC3=CC=CC1=C32 BZKUYNBAFQJRDM-UHFFFAOYSA-N 0.000 description 2
230000002763 arrhythmic effect Effects 0.000 description 2
210000001367 artery Anatomy 0.000 description 2
125000004429 atom Chemical group 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
ISAOCJYIOMOJEB-UHFFFAOYSA-N benzoin Chemical compound C=1C=CC=CC=1C(O)C(=O)C1=CC=CC=C1 ISAOCJYIOMOJEB-UHFFFAOYSA-N 0.000 description 2
OJVABJMSSDUECT-UHFFFAOYSA-L berberin sulfate Chemical compound [O-]S([O-])(=O)=O.C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2.C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 OJVABJMSSDUECT-UHFFFAOYSA-L 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
210000000481 breast Anatomy 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
206010061592 cardiac fibrillation Diseases 0.000 description 2
230000003177 cardiotonic effect Effects 0.000 description 2
210000000748 cardiovascular system Anatomy 0.000 description 2
210000001715 carotid artery Anatomy 0.000 description 2
238000007906 compression Methods 0.000 description 2
230000006835 compression Effects 0.000 description 2
238000010411 cooking Methods 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
230000004882 diastolic arterial blood pressure Effects 0.000 description 2
208000021264 digitalis poisoning Diseases 0.000 description 2
CHWPMFMUQATVNK-ARYYTZDLSA-N dihydrosporogen AO-1 Natural products O[C@H]1[C@]2(C(C)=C)O[C@@H]2[C@]2(C)[C@@H](C)[C@H](O)CCC2=C1 CHWPMFMUQATVNK-ARYYTZDLSA-N 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
230000003292 diminished effect Effects 0.000 description 2
229940030606 diuretics Drugs 0.000 description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
230000004064 dysfunction Effects 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
238000005265 energy consumption Methods 0.000 description 2
229960005139 epinephrine Drugs 0.000 description 2
230000002600 fibrillogenic effect Effects 0.000 description 2
238000001914 filtration Methods 0.000 description 2
235000013305 food Nutrition 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000007789 gas Substances 0.000 description 2
210000005095 gastrointestinal system Anatomy 0.000 description 2
238000007429 general method Methods 0.000 description 2
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
230000001077 hypotensive effect Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
239000011630 iodine Substances 0.000 description 2
229910052742 iron Inorganic materials 0.000 description 2
230000002427 irreversible effect Effects 0.000 description 2
238000006317 isomerization reaction Methods 0.000 description 2
229940039009 isoproterenol Drugs 0.000 description 2
150000002537 isoquinolines Chemical class 0.000 description 2
210000004731 jugular vein Anatomy 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
210000005246 left atrium Anatomy 0.000 description 2
210000002414 leg Anatomy 0.000 description 2
231100000053 low toxicity Toxicity 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000011418 maintenance treatment Methods 0.000 description 2
235000013372 meat Nutrition 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
230000000051 modifying effect Effects 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
230000003680 myocardial damage Effects 0.000 description 2
208000037891 myocardial injury Diseases 0.000 description 2
231100000957 no side effect Toxicity 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
229960002748 norepinephrine Drugs 0.000 description 2
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
ZHYQCBCBTQWPLC-UHFFFAOYSA-N oxyberberine Chemical compound C12=CC=3OCOC=3C=C2CCN2C1=CC1=CC=C(OC)C(OC)=C1C2=O ZHYQCBCBTQWPLC-UHFFFAOYSA-N 0.000 description 2
238000006213 oxygenation reaction Methods 0.000 description 2
QUCQEUCGKKTEBI-UHFFFAOYSA-N palmatine Chemical compound COC1=CC=C2C=C(C3=C(C=C(C(=C3)OC)OC)CC3)[N+]3=CC2=C1OC QUCQEUCGKKTEBI-UHFFFAOYSA-N 0.000 description 2
230000010412 perfusion Effects 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
208000026435 phlegm Diseases 0.000 description 2
235000021317 phosphate Nutrition 0.000 description 2
239000000902 placebo Substances 0.000 description 2
229940068196 placebo Drugs 0.000 description 2
231100000572 poisoning Toxicity 0.000 description 2
230000000607 poisoning effect Effects 0.000 description 2
239000011591 potassium Substances 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
230000002028 premature Effects 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000003449 preventive effect Effects 0.000 description 2
229960000244 procainamide Drugs 0.000 description 2
REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 2
230000008569 process Effects 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
230000010349 pulsation Effects 0.000 description 2
150000003242 quaternary ammonium salts Chemical class 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
238000012552 review Methods 0.000 description 2
238000004904 shortening Methods 0.000 description 2
230000007958 sleep Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000008247 solid mixture Substances 0.000 description 2
238000011272 standard treatment Methods 0.000 description 2
238000007619 statistical method Methods 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
230000001629 suppression Effects 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
229910052713 technetium Inorganic materials 0.000 description 2
GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 2
238000010998 test method Methods 0.000 description 2
229910052716 thallium Inorganic materials 0.000 description 2
BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 2
238000011287 therapeutic dose Methods 0.000 description 2
231100000816 toxic dose Toxicity 0.000 description 2
239000003053 toxin Substances 0.000 description 2
231100000765 toxin Toxicity 0.000 description 2
229940125725 tranquilizer Drugs 0.000 description 2
239000003204 tranquilizing agent Substances 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
JFJZZMVDLULRGK-URLMMPGGSA-O tubocurarine Chemical compound C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CCN3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 JFJZZMVDLULRGK-URLMMPGGSA-O 0.000 description 2
210000001186 vagus nerve Anatomy 0.000 description 2
208000019553 vascular disease Diseases 0.000 description 2
210000005166 vasculature Anatomy 0.000 description 2
230000003639 vasoconstrictive effect Effects 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
238000009423 ventilation Methods 0.000 description 2
210000001835 viscera Anatomy 0.000 description 2
238000005303 weighing Methods 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
RUPUUZZJJXCDHS-UHFFFAOYSA-N (+)-orientaline Natural products C1=C(O)C(OC)=CC(CC2C3=CC(O)=C(OC)C=C3CCN2C)=C1 RUPUUZZJJXCDHS-UHFFFAOYSA-N 0.000 description 1
SLRCCWJSBJZJBV-LXTVHRRPSA-N (-)-Spartein Natural products C1N2CCCC[C@@H]2[C@H]2CN3CCCC[C@@H]3[C@H]1C2 SLRCCWJSBJZJBV-LXTVHRRPSA-N 0.000 description 1
DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
LYFPBWOBIJJASK-INIZCTEOSA-N (S)-(-)-Canadine Natural products O(C)c1c(OC)ccc2c1C[N+]1[C@H](c3c(cc4OCOc4c3)CC1)C2 LYFPBWOBIJJASK-INIZCTEOSA-N 0.000 description 1
TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
VVEPUJCLNRDIEQ-UHFFFAOYSA-N 3,8,9-trimethoxy-5-methylbenzo[c]phenanthridin-5-ium-2-ol;chloride Chemical compound [Cl-].C1=C(OC)C(OC)=CC2=C[N+](C)=C3C(C=C(C(=C4)O)OC)=C4C=CC3=C21 VVEPUJCLNRDIEQ-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
GDRVFDDBLLKWRI-UHFFFAOYSA-N 4H-quinolizine Chemical compound C1=CC=CN2CC=CC=C21 GDRVFDDBLLKWRI-UHFFFAOYSA-N 0.000 description 1
SUDBRAWXUGTELR-HPFNVAMJSA-N 5-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-1h-pyrimidine-2,4-dione Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OCC1=CNC(=O)NC1=O SUDBRAWXUGTELR-HPFNVAMJSA-N 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
206010001497 Agitation Diseases 0.000 description 1
YBDPGYNCDXZFOS-UHFFFAOYSA-N Alborine Natural products O(C)c1c(CO)c2c(cc1OC)c[n+]1c(-c3c(OC)c4OCOc4cc3CC1)c2 YBDPGYNCDXZFOS-UHFFFAOYSA-N 0.000 description 1
241001136782 Alca Species 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
241000143060 Americamysis bahia Species 0.000 description 1
206010002199 Anaphylactic shock Diseases 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
206010003130 Arrhythmia supraventricular Diseases 0.000 description 1
206010003225 Arteriospasm coronary Diseases 0.000 description 1
208000002102 Atrial Premature Complexes Diseases 0.000 description 1
241000271566 Aves Species 0.000 description 1
101100223766 Bacillus subtilis (strain 168) des gene Proteins 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
VFCGRXCCUHLLIP-UHFFFAOYSA-N Berberastine Chemical compound C1=C2C(O)C[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 VFCGRXCCUHLLIP-UHFFFAOYSA-N 0.000 description 1
241000219495 Betulaceae Species 0.000 description 1
ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical class N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 1
206010004950 Birth mark Diseases 0.000 description 1
206010005746 Blood pressure fluctuation Diseases 0.000 description 1
241000255789 Bombyx mori Species 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
241000269420 Bufonidae Species 0.000 description 1
101100433727 Caenorhabditis elegans got-1.2 gene Proteins 0.000 description 1
101100509003 Caenorhabditis elegans irk-1 gene Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
208000002061 Cardiac Conduction System Disease Diseases 0.000 description 1
208000020446 Cardiac disease Diseases 0.000 description 1
206010007558 Cardiac failure chronic Diseases 0.000 description 1
206010007572 Cardiac hypertrophy Diseases 0.000 description 1
208000006029 Cardiomegaly Diseases 0.000 description 1
241000270617 Cheloniidae Species 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
241000272203 Columba Species 0.000 description 1
206010010071 Coma Diseases 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
PAPMYQLKLNRZIR-UHFFFAOYSA-N Cotarnine Chemical class C1CN(C)C(O)C2=C1C=C1OCOC1=C2OC PAPMYQLKLNRZIR-UHFFFAOYSA-N 0.000 description 1
241000238557 Decapoda Species 0.000 description 1
206010070559 Distributive shock Diseases 0.000 description 1
101100210287 Drosophila melanogaster wech gene Proteins 0.000 description 1
206010013647 Drowning Diseases 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
208000005189 Embolism Diseases 0.000 description 1
241000854350 Enicospilus group Species 0.000 description 1
OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 1
241000233866 Fungi Species 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
208000032456 Hemorrhagic Shock Diseases 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
101000635799 Homo sapiens Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Proteins 0.000 description 1
108010003272 Hyaluronate lyase Proteins 0.000 description 1
102000001974 Hyaluronidases Human genes 0.000 description 1
241000735429 Hydrastis Species 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
208000004454 Hyperalgesia Diseases 0.000 description 1
208000035154 Hyperesthesia Diseases 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010021639 Incontinence Diseases 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229930188389 Lanatoside Natural products 0.000 description 1
JAYAGJDXJIDEKI-PTGWOZRBSA-N Lanatoside C Chemical compound O([C@H]1[C@@H](OC(C)=O)C[C@@H](O[C@@H]1C)O[C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@@H]1C[C@@H]2[C@]([C@@H]3[C@H]([C@]4(CC[C@@H]([C@@]4(C)[C@H](O)C3)C=3COC(=O)C=3)O)CC2)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JAYAGJDXJIDEKI-PTGWOZRBSA-N 0.000 description 1
JAYAGJDXJIDEKI-UHFFFAOYSA-N Lanatoside C Natural products CC1OC(OC2CC3C(C4C(C5(CCC(C5(C)C(O)C4)C=4COC(=O)C=4)O)CC3)(C)CC2)CC(O)C1OC(OC1C)CC(O)C1OC(OC1C)CC(OC(C)=O)C1OC1OC(CO)C(O)C(O)C1O JAYAGJDXJIDEKI-UHFFFAOYSA-N 0.000 description 1
KGPAYJZAMGEDIQ-KRWDZBQOSA-N Laudanosine Chemical compound C1=C(OC)C(OC)=CC=C1C[C@H]1C2=CC(OC)=C(OC)C=C2CCN1C KGPAYJZAMGEDIQ-KRWDZBQOSA-N 0.000 description 1
206010049694 Left Ventricular Dysfunction Diseases 0.000 description 1
241000222736 Leishmania tropica Species 0.000 description 1
241000039951 Lithocarpus glaber Species 0.000 description 1
241000499917 Milla Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
206010069140 Myocardial depression Diseases 0.000 description 1
206010028594 Myocardial fibrosis Diseases 0.000 description 1
241001553014 Myrsine salicina Species 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
239000000006 Nitroglycerin Substances 0.000 description 1
241000283965 Ochotona princeps Species 0.000 description 1
240000007594 Oryza sativa Species 0.000 description 1
235000007164 Oryza sativa Nutrition 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
102000004316 Oxidoreductases Human genes 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
229930194309 Papaverrubine Natural products 0.000 description 1
208000008469 Peptic Ulcer Diseases 0.000 description 1
CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
241001474791 Proboscis Species 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
206010037423 Pulmonary oedema Diseases 0.000 description 1
LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
102100030852 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Human genes 0.000 description 1
QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
206010040741 Sinus bradycardia Diseases 0.000 description 1
206010041235 Snoring Diseases 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
244000028419 Styrax benzoin Species 0.000 description 1
235000000126 Styrax benzoin Nutrition 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
235000008411 Sumatra benzointree Nutrition 0.000 description 1
208000003734 Supraventricular Tachycardia Diseases 0.000 description 1
241001655798 Taku Species 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
PQECCKIOFCWGRJ-UHFFFAOYSA-N Tetrahydro-berberine Natural products C1=C2C3CC4=CC=C(OC)C(O)=C4CN3CCC2=CC2=C1OCO2 PQECCKIOFCWGRJ-UHFFFAOYSA-N 0.000 description 1
QCMQEZNBBPGFKQ-UHFFFAOYSA-N Thalisopynine Natural products CN1CCC2=C(OC)C(OC)=C(OC)C3=C2C1CC1=C3C=C(OC)C(O)=C1 QCMQEZNBBPGFKQ-UHFFFAOYSA-N 0.000 description 1
LYZGJWXNOGIVQA-UHFFFAOYSA-M Thiamylal sodium Chemical compound [Na+].CCCC(C)C1(CC=C)C(=O)NC([S-])=NC1=O LYZGJWXNOGIVQA-UHFFFAOYSA-M 0.000 description 1
FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical class C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
206010046788 Uterine haemorrhage Diseases 0.000 description 1
206010047141 Vasodilatation Diseases 0.000 description 1
206010048671 Venous stenosis Diseases 0.000 description 1
208000009729 Ventricular Premature Complexes Diseases 0.000 description 1
206010047289 Ventricular extrasystoles Diseases 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
YOAUKNYXWBTMMF-KRWDZBQOSA-N Xylopinine Chemical compound C1C2=CC(OC)=C(OC)C=C2C[C@@H]2N1CCC1=C2C=C(OC)C(OC)=C1 YOAUKNYXWBTMMF-KRWDZBQOSA-N 0.000 description 1
YOAUKNYXWBTMMF-UHFFFAOYSA-N Xylopinine Natural products C1C2=CC(OC)=C(OC)C=C2CC2N1CCC1=C2C=C(OC)C(OC)=C1 YOAUKNYXWBTMMF-UHFFFAOYSA-N 0.000 description 1
YFGQJKBUXPKSAW-ZUDKKNPISA-N [(2r,3r,4s)-6-[(2r,3s,4s)-4-hydroxy-6-[(2r,3s,4s)-4-hydroxy-6-[[(3s,9s,10s,13r,17r)-14-hydroxy-10,13-dimethyl-17-(5-oxo-2h-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-2-methyloxan-3-yl]oxy-2-methyloxan-3-y Chemical compound O([C@H]1[C@@H](OC(C)=O)CC(O[C@@H]1C)O[C@H]1[C@@H](O)CC(O[C@@H]1C)O[C@H]1[C@@H](O)CC(O[C@@H]1C)O[C@@H]1CC2[C@]([C@@H]3C(C4(CC[C@@H]([C@@]4(C)CC3)C=3COC(=O)C=3)O)CC2)(C)CC1)C1O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]1O YFGQJKBUXPKSAW-ZUDKKNPISA-N 0.000 description 1
238000002679 ablation Methods 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
235000011054 acetic acid Nutrition 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
230000004913 activation Effects 0.000 description 1
206010000891 acute myocardial infarction Diseases 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
125000005530 alkylenedioxy group Chemical group 0.000 description 1
SLRCCWJSBJZJBV-UHFFFAOYSA-N alpha-isosparteine Natural products C1N2CCCCC2C2CN3CCCCC3C1C2 SLRCCWJSBJZJBV-UHFFFAOYSA-N 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
238000002266 amputation Methods 0.000 description 1
239000002269 analeptic agent Substances 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
230000036783 anaphylactic response Effects 0.000 description 1
150000008064 anhydrides Chemical group 0.000 description 1
230000001078 anti-cholinergic effect Effects 0.000 description 1
230000003474 anti-emetic effect Effects 0.000 description 1
230000003373 anti-fouling effect Effects 0.000 description 1
230000003276 anti-hypertensive effect Effects 0.000 description 1
230000001754 anti-pyretic effect Effects 0.000 description 1
239000002221 antipyretic Substances 0.000 description 1
229940111121 antirheumatic drug quinolines Drugs 0.000 description 1
239000003699 antiulcer agent Substances 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
208000002399 aphthous stomatitis Diseases 0.000 description 1
CAWXSAHEALOABD-HXPMCKFVSA-N apocavidine Natural products COc1ccc2[C@H]3[C@@H](C)c4ccc5OCOc5c4CN3CCc2c1 CAWXSAHEALOABD-HXPMCKFVSA-N 0.000 description 1
230000004596 appetite loss Effects 0.000 description 1
125000003710 aryl alkyl group Chemical group 0.000 description 1
235000019606 astringent taste Nutrition 0.000 description 1
230000001746 atrial effect Effects 0.000 description 1
206010003668 atrial tachycardia Diseases 0.000 description 1
210000001992 atrioventricular node Anatomy 0.000 description 1
230000002567 autonomic effect Effects 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
229960002319 barbital Drugs 0.000 description 1
238000010009 beating Methods 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
229960002130 benzoin Drugs 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
BRLDZKPJJNASGG-UHFFFAOYSA-N berbine Chemical compound C1=CC=C2CN3CCC4=CC=CC=C4C3CC2=C1 BRLDZKPJJNASGG-UHFFFAOYSA-N 0.000 description 1
102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
229940097320 beta blocking agent Drugs 0.000 description 1
230000000035 biogenic effect Effects 0.000 description 1
230000008033 biological extinction Effects 0.000 description 1
230000033558 biomineral tissue development Effects 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
230000006406 biphasic response Effects 0.000 description 1
239000002981 blocking agent Substances 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
210000001772 blood platelet Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
230000036471 bradycardia Effects 0.000 description 1
208000006218 bradycardia Diseases 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
210000004375 bundle of his Anatomy 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
210000001217 buttock Anatomy 0.000 description 1
239000011575 calcium Chemical group 0.000 description 1
229910052791 calcium Chemical group 0.000 description 1
VZTUIEROBZXUFA-UHFFFAOYSA-N canadine Chemical compound C1=C2C3CC4=CC=C(OC)C(OC)=C4CN3CCC2=CC2=C1OCO2 VZTUIEROBZXUFA-UHFFFAOYSA-N 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
210000004903 cardiac system Anatomy 0.000 description 1
206010007625 cardiogenic shock Diseases 0.000 description 1
230000009084 cardiovascular function Effects 0.000 description 1
210000001159 caudate nucleus Anatomy 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
238000011976 chest X-ray Methods 0.000 description 1
230000001055 chewing effect Effects 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
239000000812 cholinergic antagonist Substances 0.000 description 1
230000002057 chronotropic effect Effects 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
230000035602 clotting Effects 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
206010009887 colitis Diseases 0.000 description 1
230000001447 compensatory effect Effects 0.000 description 1
229940126214 compound 3 Drugs 0.000 description 1
230000002508 compound effect Effects 0.000 description 1
238000003271 compound fluorescence assay Methods 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
239000000039 congener Substances 0.000 description 1
208000028831 congenital heart disease Diseases 0.000 description 1
230000002517 constrictor effect Effects 0.000 description 1
239000002872 contrast media Substances 0.000 description 1
238000001816 cooling Methods 0.000 description 1
ZAODQVCWAXRSRG-UHFFFAOYSA-N coralydine Natural products CC1C2=CC(OC)=C(OC)C=C2CC2N1CCC1=C2C=C(OC)C(OC)=C1 ZAODQVCWAXRSRG-UHFFFAOYSA-N 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
238000012937 correction Methods 0.000 description 1
XPOJSWHIKCNLEQ-UHFFFAOYSA-N cryptopine Chemical compound C1CN(C)CC2=C(OCO3)C3=CC=C2CC(=O)C2=C1C=C(OC)C(OC)=C2 XPOJSWHIKCNLEQ-UHFFFAOYSA-N 0.000 description 1
RHJBGPMDJNBXPF-UHFFFAOYSA-N cryptopine Natural products COc1cc2CCN(C)c3cc4OCOc4cc3CCC(=O)c2cc1OC RHJBGPMDJNBXPF-UHFFFAOYSA-N 0.000 description 1
238000009109 curative therapy Methods 0.000 description 1
LKLWVKCEYSPQHL-KKSFZXQISA-O cyclanoline Chemical compound C12=CC(O)=C(OC)C=C2CC[N@+]2(C)[C@H]1CC1=CC=C(OC)C(O)=C1C2 LKLWVKCEYSPQHL-KKSFZXQISA-O 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
230000002354 daily effect Effects 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000000994 depressogenic effect Effects 0.000 description 1
101150097617 desA gene Proteins 0.000 description 1
INUNXTSAACVKJS-OAQYLSRUSA-N dextromoramide Chemical compound C([C@@H](C)C(C(=O)N1CCCC1)(C=1C=CC=CC=1)C=1C=CC=CC=1)N1CCOCC1 INUNXTSAACVKJS-OAQYLSRUSA-N 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
229940039227 diagnostic agent Drugs 0.000 description 1
239000000032 diagnostic agent Substances 0.000 description 1
229940082657 digitalis glycosides Drugs 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000007323 disproportionation reaction Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
230000001882 diuretic effect Effects 0.000 description 1
229960003638 dopamine Drugs 0.000 description 1
230000003291 dopaminomimetic effect Effects 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000003255 drug test Methods 0.000 description 1
238000002635 electroconvulsive therapy Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
125000001033 ether group Chemical group 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
230000002169 extracardiac Effects 0.000 description 1
210000003414 extremity Anatomy 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
230000004438 eyesight Effects 0.000 description 1
239000004744 fabric Substances 0.000 description 1
230000001815 facial effect Effects 0.000 description 1
206010016256 fatigue Diseases 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
210000003746 feather Anatomy 0.000 description 1
210000003608 fece Anatomy 0.000 description 1
210000003191 femoral vein Anatomy 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
238000002594 fluoroscopy Methods 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
210000000245 forearm Anatomy 0.000 description 1
239000012458 free base Substances 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
230000004927 fusion Effects 0.000 description 1
230000005176 gastrointestinal motility Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229960003711 glyceryl trinitrate Drugs 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000012010 growth Effects 0.000 description 1
235000019382 gum benzoic Nutrition 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
210000003128 head Anatomy 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
230000035876 healing Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
230000005831 heart abnormality Effects 0.000 description 1
210000005003 heart tissue Anatomy 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
239000002663 humin Substances 0.000 description 1
229960002773 hyaluronidase Drugs 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
125000002768 hydroxyalkyl group Chemical group 0.000 description 1
230000000544 hyperemic effect Effects 0.000 description 1
230000036543 hypotension Effects 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
210000001153 interneuron Anatomy 0.000 description 1
230000035987 intoxication Effects 0.000 description 1
231100000566 intoxication Toxicity 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
230000026045 iodination Effects 0.000 description 1
238000006192 iodination reaction Methods 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
230000001788 irregular Effects 0.000 description 1
208000021803 junctional tachycardia Diseases 0.000 description 1
229910000833 kovar Inorganic materials 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229960002614 lanatoside c Drugs 0.000 description 1
KGPAYJZAMGEDIQ-UHFFFAOYSA-N laudanosine Natural products C1=C(OC)C(OC)=CC=C1CC1C2=CC(OC)=C(OC)C=C2CCN1C KGPAYJZAMGEDIQ-UHFFFAOYSA-N 0.000 description 1
230000003902 lesion Effects 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
231100000636 lethal dose Toxicity 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
FVRABHGHBLRNNR-UHFFFAOYSA-N liriodenine Natural products O=C1C=CC=c2c1cc3nccc4cc5OCOc5c2c34 FVRABHGHBLRNNR-UHFFFAOYSA-N 0.000 description 1
230000003908 liver function Effects 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
208000019017 loss of appetite Diseases 0.000 description 1
235000021266 loss of appetite Nutrition 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000009115 maintenance therapy Methods 0.000 description 1
206010025482 malaise Diseases 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
150000002688 maleic acid derivatives Chemical class 0.000 description 1
230000036244 malformation Effects 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
238000002483 medication Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
208000037819 metastatic cancer Diseases 0.000 description 1
208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
239000008267 milk Substances 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
230000004899 motility Effects 0.000 description 1
230000010016 myocardial function Effects 0.000 description 1
230000008693 nausea Effects 0.000 description 1
208000018305 neoplasm of myocardium Diseases 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
229960001597 nifedipine Drugs 0.000 description 1
150000002823 nitrates Chemical class 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
230000001129 nonadrenergic effect Effects 0.000 description 1
FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 1
238000009206 nuclear medicine Methods 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
210000004789 organ system Anatomy 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000002895 organic esters Chemical class 0.000 description 1
230000010355 oscillation Effects 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 1
OLIRVMPRFWLUGS-UHFFFAOYSA-N oxyberberine Natural products COc1ccc2C=C3N(CCc4cc5OCCOc5cc34)C(=O)c2c1OC OLIRVMPRFWLUGS-UHFFFAOYSA-N 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
230000036407 pain Effects 0.000 description 1
229940096717 pamine Drugs 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
208000008510 paroxysmal tachycardia Diseases 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000004963 pathophysiological condition Effects 0.000 description 1
230000001991 pathophysiological effect Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
208000011906 peptic ulcer disease Diseases 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
239000000810 peripheral vasodilating agent Substances 0.000 description 1
229960002116 peripheral vasodilator Drugs 0.000 description 1
238000001558 permutation test Methods 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
125000001484 phenothiazinyl group Chemical class C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
229960002036 phenytoin Drugs 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
229960001416 pilocarpine Drugs 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
235000015277 pork Nutrition 0.000 description 1
239000000843 powder Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
229960003712 propranolol Drugs 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
230000008430 psychophysiology Effects 0.000 description 1
210000001147 pulmonary artery Anatomy 0.000 description 1
208000005333 pulmonary edema Diseases 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
230000000541 pulsatile effect Effects 0.000 description 1
210000001747 pupil Anatomy 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000013094 purity test Methods 0.000 description 1
230000001698 pyrogenic effect Effects 0.000 description 1
125000001453 quaternary ammonium group Chemical group 0.000 description 1
150000003248 quinolines Chemical class 0.000 description 1
230000005855 radiation Effects 0.000 description 1
239000000941 radioactive substance Substances 0.000 description 1
238000011552 rat model Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000034622 regulation of systemic arterial blood pressure by atrial baroreceptor feedback Effects 0.000 description 1
QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
229960003147 reserpine Drugs 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
BNUZUOWRDKPBQR-UHFFFAOYSA-N reticuline Natural products CN1CCC2=CC(OC)=CC=C2C1CC1=CC=C(OC)C(O)=C1 BNUZUOWRDKPBQR-UHFFFAOYSA-N 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
235000009566 rice Nutrition 0.000 description 1
210000005245 right atrium Anatomy 0.000 description 1
210000005241 right ventricle Anatomy 0.000 description 1
MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
229910052701 rubidium Inorganic materials 0.000 description 1
IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 description 1
LSMIOFMZNVEEBR-ICLSSMQGSA-N scilliroside Chemical compound C=1([C@@H]2[C@@]3(C)CC[C@H]4[C@@]([C@]3(CC2)O)(O)C[C@H](C2=C[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)CC[C@@]24C)OC(=O)C)C=CC(=O)OC=1 LSMIOFMZNVEEBR-ICLSSMQGSA-N 0.000 description 1
238000013077 scoring method Methods 0.000 description 1
230000009291 secondary effect Effects 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
230000001624 sedative effect Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
238000010008 shearing Methods 0.000 description 1
235000020083 shōchū Nutrition 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
230000004622 sleep time Effects 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
235000009518 sodium iodide Nutrition 0.000 description 1
238000000527 sonication Methods 0.000 description 1
239000004071 soot Substances 0.000 description 1
229960001945 sparteine Drugs 0.000 description 1
SLRCCWJSBJZJBV-AJNGGQMLSA-N sparteine Chemical compound C1N2CCCC[C@H]2[C@@H]2CN3CCCC[C@H]3[C@H]1C2 SLRCCWJSBJZJBV-AJNGGQMLSA-N 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
230000003393 splenic effect Effects 0.000 description 1
208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
238000005507 spraying Methods 0.000 description 1
230000007480 spreading Effects 0.000 description 1
238000003892 spreading Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
239000003206 sterilizing agent Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
239000004575 stone Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000005728 strengthening Methods 0.000 description 1
FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
229940127230 sympathomimetic drug Drugs 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
238000012353 t test Methods 0.000 description 1
229910052715 tantalum Inorganic materials 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
235000012976 tarts Nutrition 0.000 description 1
ZCTJIMXXSXQXRI-UHFFFAOYSA-N thaliblastine Natural products CN1CCC2=CC(OC)=C(OC)C3=C2C1CC1=C3C=C(OC)C(OC2=C(CC3C4=CC(OC)=C(OC)C=C4CCN3C)C=C(C(=C2)OC)OC)=C1 ZCTJIMXXSXQXRI-UHFFFAOYSA-N 0.000 description 1
ZCTJIMXXSXQXRI-KYJUHHDHSA-N thalicarpine Chemical compound CN1CCC2=CC(OC)=C(OC)C3=C2[C@@H]1CC1=C3C=C(OC)C(OC2=C(C[C@H]3C4=CC(OC)=C(OC)C=C4CCN3C)C=C(C(=C2)OC)OC)=C1 ZCTJIMXXSXQXRI-KYJUHHDHSA-N 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
238000009210 therapy by ultrasound Methods 0.000 description 1
229960001525 thiamylal sodium Drugs 0.000 description 1
210000000115 thoracic cavity Anatomy 0.000 description 1
229960004605 timolol Drugs 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
230000001256 tonic effect Effects 0.000 description 1
210000003437 trachea Anatomy 0.000 description 1
238000012549 training Methods 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000032258 transport Effects 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
230000006496 vascular abnormality Effects 0.000 description 1
239000002550 vasoactive agent Substances 0.000 description 1
230000025033 vasoconstriction Effects 0.000 description 1
239000005526 vasoconstrictor agent Substances 0.000 description 1
230000000304 vasodilatating effect Effects 0.000 description 1
230000001457 vasomotor Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
229960001722 verapamil Drugs 0.000 description 1
239000000273 veterinary drug Substances 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
239000002699 waste material Substances 0.000 description 1
230000004580 weight loss Effects 0.000 description 1